Jean-Pierre Nordmann

1909 Ventures is an investment vehicle backed by the 2021A SSE MBA cohort. We invest in early-stage startups with a bit of cash and a lot of network.

1909 Ventures is an investment vehicle backed by the 2021A SSE MBA cohort. We invest in early-stage startups with a bit of cash and a lot of network.

Closar AI (Vizu Health) is an early-stage start-up revolutionizing precision healthcare through patient-generated wearable data. With €150k in funding, we are developing a platform that leverages AI to visualize and analyze health data, helping providers deliver personalized care. Precision healthcare could save $5,000 billion and 7 billion years of life, and wearable devices, generating up to 10,000 data points per day, are key to unlocking this potential. Wearables continuously monitor vital signs such as heart rate, respiration, sleep, stress, and glucose, offering a holistic view of patients health. This data allows for individualized anomaly detection, evidence-based symptom monitoring, and early medical issue detection based on long-term trends and correlations between biomarkers. Supported by studies from Stanford, Oxford, and other leading institutions, wearable data is proven to improve health outcomes. Yet, healthcare professionals struggle to effectively utilize this data. Closar AI bridges this gap with mobile and web apps and AI-powered anomaly detection, offering a user-friendly interface that helps professionals access, understand, and act on wearable data. Unlike other solutions, our platform requires no integration with EHR systems, enabling faster adoption and scalability. We offer unified compatibility across all devices, allowing clinics to attract and retain patients with cost-effective, cutting-edge solutions. Incorporated in January 2024, we’re already gaining interest from major clinic groups. By being the first to connect both patients and professionals with wearable data, we aim to dominate this emerging "blue ocean" market. With a first-mover advantage, Closar AI is poised to set the standard for wearable data-driven healthcare, creating a "patients-to-professionals" spreading effect that accelerates adoption and builds a hard-to-dislodge market presence. Now is the time to unlock the era of precision healthcare.

nordmann est un cabinet disposant des meilleurs techniques de conseil en stratégie et management. Nous dédions nos savoir-faire prioritairement au secteur de la santé et avons été labellisé « Excellent » par le Magazine Décideurs fin 2018 (classement consultable ici : https://www.leadersleague.com/fr/classements/strategie-organisation-management-secteur-sante-industrie-pharmaceutique-classements-2018-cabinet-de-conseils-france). Notre ADN c’est la qualité : de nos prestations, de l’intérêt de nos missions, de nos savoir-faire, de notre fonctionnement interne, de nos locaux, de notre équilibre vie professionnelle / vie personnelle, ... Notre approche « par principe, la qualité au cœur de notre engagement » a déjà séduit une dizaine de collaborateurs. Vous pouvez voir quelques photos et vidéos de l’équipe sur Welcome To The Jungle (lien ici : https://www.welcometothejungle.co/companies/nordmann) nordmann accompagne l’ensemble des décisions et projets des équipes dirigeantes : stratégie d’investissement, stratégie d’établissement et d’activités, stratégies organisationnelles, transformations organisationnelles, management et gouvernance. Depuis 2015, nous avons réalisé plus de 50 missions en lien avec la santé : Ministère/ARS, GHT/CHU/CH, clinique, industrie (références consultables ici : http://jpnordmann.wixsite.com/nordmannconseil-copy/copie-de-nos-references-1). Le cabinet est référencé au niveau national par les principaux acteurs.